BORGESON JOHN A. sold $2.7M of KOD
BORGESON JOHN A. (Chief Financial Officer) sold 30,000 shares of Kodiak Sciences Inc. (KOD) at an average of $90.01 ($87.67–$94.91, $2.70M total) across 8 trades on 2026-10-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds transparency but may prompt short‑term traders to sell, especially given the CFO’s role.
Market read
Primary insider sale filing; modest size but noteworthy due to CFO involvement.
What to watch
The CFO may be diversifying personal holdings; the company’s pipeline and recent data releases remain unchanged.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates the sale was pre‑arranged, reducing speculation about timing.
Ticker impact
CFO John A. Borgeson sold 30,000 shares for $2.7M via a 10b5‑1 plan, reducing his stake to 211,930 shares.
likely downward pressure as the market prices in the CFO's share disposal
A senior officer is reducing ownership; while the amount is modest, such sales often trigger short‑term selling pressure.
Market effects
Minimal impact on the broader biotech sector; insider sales are company‑specific.
No regional effect beyond the stock's own trading community.
Limited global relevance; only investors in Kodiak Sciences are directly affected.
Counterpoint
The sale could be routine under a pre‑arranged plan and not reflect negative fundamentals.
Key entities
- companyKodiak Sciences Inc.
Biotech firm developing therapies for liver disease.
- personJohn A. Borgeson
Chief Financial Officer of Kodiak Sciences.
